NCT07522697
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07522697 |
| Title | Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 (MITO END-4) |
| Acronym | MITO END-4 |
| Recruitment | Not yet recruiting |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | National Cancer Institute, Naples |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ITA |
CKB BOOST